Wells Fargo & Company Trevi Therapeutics, Inc. Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding TRVI
# of Institutions
74Shares Held
54.3MCall Options Held
15.6KPut Options Held
0-
Nea Management Company, LLC Timonium, MD11.4MShares$38.2 Million3.2% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$24.8 Million1.3% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$16.9 Million0.44% of portfolio
-
Viking Global Investors LP4.4MShares$14.8 Million0.05% of portfolio
-
Vr Adviser, LLC New York, NY3.42MShares$11.5 Million1.12% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $196M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...